nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—ABL1—Parkinson's disease	0.633	0.844	CbGaD
Afatinib—ABCB1—Parkinson's disease	0.117	0.156	CbGaD
Afatinib—PHKG2—hindbrain—Parkinson's disease	0.00439	0.0535	CbGeAlD
Afatinib—DYRK1A—hindbrain—Parkinson's disease	0.0038	0.0463	CbGeAlD
Afatinib—PHKG2—brainstem—Parkinson's disease	0.00252	0.0307	CbGeAlD
Afatinib—ERBB2—embryo—Parkinson's disease	0.00247	0.0301	CbGeAlD
Afatinib—ERBB4—embryo—Parkinson's disease	0.00247	0.0301	CbGeAlD
Afatinib—Vandetanib—ABL1—Parkinson's disease	0.00231	0.703	CrCbGaD
Afatinib—ERBB4—brainstem—Parkinson's disease	0.00226	0.0276	CbGeAlD
Afatinib—ERBB4—forebrain—Parkinson's disease	0.00218	0.0266	CbGeAlD
Afatinib—DYRK1A—brainstem—Parkinson's disease	0.00218	0.0265	CbGeAlD
Afatinib—DYRK1A—forebrain—Parkinson's disease	0.0021	0.0256	CbGeAlD
Afatinib—ERBB4—cardiovascular system—Parkinson's disease	0.00185	0.0225	CbGeAlD
Afatinib—ERBB2—cardiovascular system—Parkinson's disease	0.00185	0.0225	CbGeAlD
Afatinib—DYRK1A—cardiovascular system—Parkinson's disease	0.00178	0.0217	CbGeAlD
Afatinib—PHKG2—medulla oblongata—Parkinson's disease	0.00175	0.0214	CbGeAlD
Afatinib—ABL1—hindbrain—Parkinson's disease	0.00165	0.0201	CbGeAlD
Afatinib—ERBB4—medulla oblongata—Parkinson's disease	0.00158	0.0192	CbGeAlD
Afatinib—EPHA6—head—Parkinson's disease	0.00144	0.0176	CbGeAlD
Afatinib—ERBB4—midbrain—Parkinson's disease	0.00144	0.0176	CbGeAlD
Afatinib—ERBB4—spinal cord—Parkinson's disease	0.00141	0.0171	CbGeAlD
Afatinib—PHKG2—head—Parkinson's disease	0.00139	0.0169	CbGeAlD
Afatinib—EPHA6—nervous system—Parkinson's disease	0.00137	0.0167	CbGeAlD
Afatinib—HIPK4—brain—Parkinson's disease	0.00132	0.0161	CbGeAlD
Afatinib—PHKG2—nervous system—Parkinson's disease	0.00132	0.0161	CbGeAlD
Afatinib—EPHA6—central nervous system—Parkinson's disease	0.00132	0.016	CbGeAlD
Afatinib—PHKG2—central nervous system—Parkinson's disease	0.00127	0.0155	CbGeAlD
Afatinib—ERBB2—head—Parkinson's disease	0.00125	0.0152	CbGeAlD
Afatinib—ERBB4—head—Parkinson's disease	0.00125	0.0152	CbGeAlD
Afatinib—PHKG2—cerebellum—Parkinson's disease	0.00124	0.0151	CbGeAlD
Afatinib—DYRK1A—head—Parkinson's disease	0.0012	0.0147	CbGeAlD
Afatinib—ERBB2—nervous system—Parkinson's disease	0.00119	0.0144	CbGeAlD
Afatinib—ERBB4—nervous system—Parkinson's disease	0.00119	0.0144	CbGeAlD
Afatinib—ERBB4—central nervous system—Parkinson's disease	0.00114	0.0139	CbGeAlD
Afatinib—ERBB2—central nervous system—Parkinson's disease	0.00114	0.0139	CbGeAlD
Afatinib—DYRK1A—nervous system—Parkinson's disease	0.00114	0.0139	CbGeAlD
Afatinib—ERBB2—cerebellum—Parkinson's disease	0.00112	0.0136	CbGeAlD
Afatinib—ERBB4—cerebellum—Parkinson's disease	0.00112	0.0136	CbGeAlD
Afatinib—DYRK1A—central nervous system—Parkinson's disease	0.0011	0.0134	CbGeAlD
Afatinib—IRAK1—midbrain—Parkinson's disease	0.00108	0.0131	CbGeAlD
Afatinib—DYRK1A—cerebellum—Parkinson's disease	0.00107	0.0131	CbGeAlD
Afatinib—EPHA6—brain—Parkinson's disease	0.00104	0.0127	CbGeAlD
Afatinib—ABL1—embryo—Parkinson's disease	0.00103	0.0126	CbGeAlD
Afatinib—PHKG2—brain—Parkinson's disease	0.00101	0.0123	CbGeAlD
Afatinib—ABL1—brainstem—Parkinson's disease	0.000948	0.0115	CbGeAlD
Afatinib—EGFR—cerebellum—Parkinson's disease	0.000945	0.0115	CbGeAlD
Afatinib—ERBB2—brain—Parkinson's disease	0.000906	0.011	CbGeAlD
Afatinib—ERBB4—brain—Parkinson's disease	0.000906	0.011	CbGeAlD
Afatinib—DYRK1A—brain—Parkinson's disease	0.000872	0.0106	CbGeAlD
Afatinib—IRAK1—cerebellum—Parkinson's disease	0.000834	0.0102	CbGeAlD
Afatinib—ABL1—cardiovascular system—Parkinson's disease	0.000773	0.00942	CbGeAlD
Afatinib—EGFR—brain—Parkinson's disease	0.000768	0.00936	CbGeAlD
Afatinib—IRAK1—brain—Parkinson's disease	0.000678	0.00826	CbGeAlD
Afatinib—ABL1—medulla oblongata—Parkinson's disease	0.000661	0.00805	CbGeAlD
Afatinib—ABL1—midbrain—Parkinson's disease	0.000604	0.00736	CbGeAlD
Afatinib—ABL1—spinal cord—Parkinson's disease	0.000589	0.00718	CbGeAlD
Afatinib—Gefitinib—CYP2D6—Parkinson's disease	0.000569	0.173	CrCbGaD
Afatinib—ABL1—head—Parkinson's disease	0.000524	0.00638	CbGeAlD
Afatinib—ABL1—nervous system—Parkinson's disease	0.000497	0.00605	CbGeAlD
Afatinib—ABL1—central nervous system—Parkinson's disease	0.000478	0.00582	CbGeAlD
Afatinib—ABL1—cerebellum—Parkinson's disease	0.000467	0.00569	CbGeAlD
Afatinib—ABCG2—medulla oblongata—Parkinson's disease	0.000417	0.00508	CbGeAlD
Afatinib—Gefitinib—ABCB1—Parkinson's disease	0.000407	0.124	CrCbGaD
Afatinib—ABCG2—midbrain—Parkinson's disease	0.000381	0.00464	CbGeAlD
Afatinib—ABL1—brain—Parkinson's disease	0.00038	0.00462	CbGeAlD
Afatinib—ABCG2—spinal cord—Parkinson's disease	0.000372	0.00453	CbGeAlD
Afatinib—ABCB1—embryo—Parkinson's disease	0.000322	0.00392	CbGeAlD
Afatinib—ABCG2—cerebellum—Parkinson's disease	0.000295	0.00359	CbGeAlD
Afatinib—ABCB1—forebrain—Parkinson's disease	0.000284	0.00347	CbGeAlD
Afatinib—ABCB1—cardiovascular system—Parkinson's disease	0.000241	0.00293	CbGeAlD
Afatinib—ABCG2—brain—Parkinson's disease	0.000239	0.00292	CbGeAlD
Afatinib—ABCB1—medulla oblongata—Parkinson's disease	0.000206	0.0025	CbGeAlD
Afatinib—ABCB1—midbrain—Parkinson's disease	0.000188	0.00229	CbGeAlD
Afatinib—ABCB1—spinal cord—Parkinson's disease	0.000183	0.00223	CbGeAlD
Afatinib—ABCB1—head—Parkinson's disease	0.000163	0.00198	CbGeAlD
Afatinib—ABCB1—nervous system—Parkinson's disease	0.000154	0.00188	CbGeAlD
Afatinib—ABCB1—central nervous system—Parkinson's disease	0.000149	0.00181	CbGeAlD
Afatinib—ABCB1—cerebellum—Parkinson's disease	0.000145	0.00177	CbGeAlD
Afatinib—ABCB1—brain—Parkinson's disease	0.000118	0.00144	CbGeAlD
Afatinib—LCK—Cytokine Signaling in Immune system—IL1B—Parkinson's disease	2.39e-05	0.000145	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PENK—Parkinson's disease	2.38e-05	0.000144	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAG—Parkinson's disease	2.38e-05	0.000144	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—INSR—Parkinson's disease	2.37e-05	0.000144	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB4—IL6—Parkinson's disease	2.37e-05	0.000144	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—TNF—Parkinson's disease	2.36e-05	0.000144	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—DRD3—Parkinson's disease	2.36e-05	0.000143	CbGpPWpGaD
Afatinib—ABL1—Immune System—ADRBK1—Parkinson's disease	2.36e-05	0.000143	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TALDO1—Parkinson's disease	2.35e-05	0.000143	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—OMD—Parkinson's disease	2.35e-05	0.000143	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—CASP3—Parkinson's disease	2.35e-05	0.000142	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—CP—Parkinson's disease	2.32e-05	0.000141	CbGpPWpGaD
Afatinib—LCK—Downstream signaling of activated FGFR—IL6—Parkinson's disease	2.32e-05	0.000141	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HGF—Parkinson's disease	2.31e-05	0.00014	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAG—Parkinson's disease	2.29e-05	0.000139	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PENK—Parkinson's disease	2.29e-05	0.000139	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB4—IL6—Parkinson's disease	2.28e-05	0.000139	CbGpPWpGaD
Afatinib—EGFR—Downstream signal transduction—IL6—Parkinson's disease	2.26e-05	0.000137	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR—IL6—Parkinson's disease	2.25e-05	0.000137	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—FGB—Parkinson's disease	2.24e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Signaling by ERBB2—IL6—Parkinson's disease	2.24e-05	0.000136	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—MAPK8—Parkinson's disease	2.24e-05	0.000136	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HTR1A—Parkinson's disease	2.23e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—DAP12 signaling—IL6—Parkinson's disease	2.23e-05	0.000135	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NDUFB11—Parkinson's disease	2.23e-05	0.000135	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—ADRBK1—Parkinson's disease	2.21e-05	0.000134	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TAC1—Parkinson's disease	2.2e-05	0.000133	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IGF2—Parkinson's disease	2.19e-05	0.000133	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PLA2G6—Parkinson's disease	2.19e-05	0.000133	CbGpPWpGaD
Afatinib—LCK—Downstream signal transduction—IL6—Parkinson's disease	2.18e-05	0.000132	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PDYN—Parkinson's disease	2.18e-05	0.000132	CbGpPWpGaD
Afatinib—IRAK1—Cytokine Signaling in Immune system—IL6—Parkinson's disease	2.17e-05	0.000132	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR—IL6—Parkinson's disease	2.17e-05	0.000132	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MAOB—Parkinson's disease	2.17e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Signaling by ERBB2—IL6—Parkinson's disease	2.16e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—MAPK8—Parkinson's disease	2.16e-05	0.000131	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—DRD1—Parkinson's disease	2.16e-05	0.000131	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IGF2—Parkinson's disease	2.16e-05	0.000131	CbGpPWpGaD
Afatinib—LCK—DAP12 signaling—IL6—Parkinson's disease	2.15e-05	0.00013	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—DRD2—Parkinson's disease	2.14e-05	0.00013	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HTR7—Parkinson's disease	2.14e-05	0.00013	CbGpPWpGaD
Afatinib—IRAK1—Signaling by NGF—IL6—Parkinson's disease	2.14e-05	0.00013	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GCH1—Parkinson's disease	2.13e-05	0.000129	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IGF1R—Parkinson's disease	2.12e-05	0.000128	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—INS—Parkinson's disease	2.11e-05	0.000128	CbGpPWpGaD
Afatinib—EGFR—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	2.1e-05	0.000127	CbGpPWpGaD
Afatinib—EGFR—DAP12 interactions—IL6—Parkinson's disease	2.1e-05	0.000127	CbGpPWpGaD
Afatinib—EGFR—Signaling by FGFR in disease—IL6—Parkinson's disease	2.1e-05	0.000127	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PDYN—Parkinson's disease	2.1e-05	0.000127	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—EDN1—Parkinson's disease	2.09e-05	0.000127	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—DRD3—Parkinson's disease	2.09e-05	0.000127	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IGF1R—Parkinson's disease	2.08e-05	0.000127	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR—IL6—Parkinson's disease	2.08e-05	0.000126	CbGpPWpGaD
Afatinib—ERBB2—Disease—INS—Parkinson's disease	2.07e-05	0.000126	CbGpPWpGaD
Afatinib—EGFR—Signaling by EGFR in Cancer—IL6—Parkinson's disease	2.06e-05	0.000125	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—EDN1—Parkinson's disease	2.06e-05	0.000125	CbGpPWpGaD
Afatinib—EGFR—Signaling by PDGF—IL6—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GFAP—Parkinson's disease	2.05e-05	0.000124	CbGpPWpGaD
Afatinib—ERBB4—Disease—INS—Parkinson's disease	2.04e-05	0.000124	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—GRM5—Parkinson's disease	2.02e-05	0.000123	CbGpPWpGaD
Afatinib—LCK—DAP12 interactions—IL6—Parkinson's disease	2.02e-05	0.000123	CbGpPWpGaD
Afatinib—LCK—Signaling by FGFR in disease—IL6—Parkinson's disease	2.02e-05	0.000123	CbGpPWpGaD
Afatinib—LCK—Fc epsilon receptor (FCERI) signaling—IL6—Parkinson's disease	2.02e-05	0.000123	CbGpPWpGaD
Afatinib—EGFR—Immune System—ADRBK1—Parkinson's disease	2.02e-05	0.000122	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR—IL6—Parkinson's disease	2e-05	0.000122	CbGpPWpGaD
Afatinib—LCK—Signaling by EGFR in Cancer—IL6—Parkinson's disease	1.99e-05	0.000121	CbGpPWpGaD
Afatinib—LCK—Signaling by PDGF—IL6—Parkinson's disease	1.98e-05	0.00012	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GFAP—Parkinson's disease	1.97e-05	0.00012	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—ADRBK1—Parkinson's disease	1.95e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—GRM5—Parkinson's disease	1.95e-05	0.000118	CbGpPWpGaD
Afatinib—LCK—Immune System—ADRBK1—Parkinson's disease	1.94e-05	0.000118	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—NGF—Parkinson's disease	1.92e-05	0.000117	CbGpPWpGaD
Afatinib—ERBB2—Developmental Biology—IL6—Parkinson's disease	1.91e-05	0.000116	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—MAPK8—Parkinson's disease	1.91e-05	0.000116	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—FBP1—Parkinson's disease	1.89e-05	0.000115	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GBA—Parkinson's disease	1.89e-05	0.000115	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—DBH—Parkinson's disease	1.89e-05	0.000115	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—NGF—Parkinson's disease	1.89e-05	0.000115	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HTR7—Parkinson's disease	1.89e-05	0.000115	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—DRD2—Parkinson's disease	1.89e-05	0.000115	CbGpPWpGaD
Afatinib—EGFR—Disease—ADRBK1—Parkinson's disease	1.86e-05	0.000113	CbGpPWpGaD
Afatinib—EGFR—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	1.86e-05	0.000113	CbGpPWpGaD
Afatinib—EGFR—Disease—HSPA1A—Parkinson's disease	1.85e-05	0.000112	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HTR2A—Parkinson's disease	1.83e-05	0.000111	CbGpPWpGaD
Afatinib—PHKG2—Disease—IL6—Parkinson's disease	1.83e-05	0.000111	CbGpPWpGaD
Afatinib—ABL1—Immune System—HGF—Parkinson's disease	1.81e-05	0.00011	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HTR2A—Parkinson's disease	1.8e-05	0.000109	CbGpPWpGaD
Afatinib—EGFR—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—Parkinson's disease	1.79e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Disease—ADRBK1—Parkinson's disease	1.79e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—NGF signalling via TRKA from the plasma membrane—IL6—Parkinson's disease	1.79e-05	0.000109	CbGpPWpGaD
Afatinib—LCK—Disease—HSPA1A—Parkinson's disease	1.78e-05	0.000108	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGF20—Parkinson's disease	1.77e-05	0.000108	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADORA2A—Parkinson's disease	1.72e-05	0.000104	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—EDN1—Parkinson's disease	1.71e-05	0.000104	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGF20—Parkinson's disease	1.71e-05	0.000104	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—APOE—Parkinson's disease	1.7e-05	0.000103	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—Parkinson's disease	1.7e-05	0.000103	CbGpPWpGaD
Afatinib—ERBB2—Innate Immune System—IL6—Parkinson's disease	1.69e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL1B—Parkinson's disease	1.68e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—APOE—Parkinson's disease	1.67e-05	0.000102	CbGpPWpGaD
Afatinib—ERBB4—Innate Immune System—IL6—Parkinson's disease	1.66e-05	0.000101	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADORA2A—Parkinson's disease	1.66e-05	0.000101	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Parkinson's disease	1.66e-05	0.000101	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL1B—Parkinson's disease	1.65e-05	0.0001	CbGpPWpGaD
Afatinib—EGFR—Immune System—ABL1—Parkinson's disease	1.64e-05	9.98e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP2D6—Parkinson's disease	1.61e-05	9.77e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—CYCS—Parkinson's disease	1.59e-05	9.65e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL1B—Parkinson's disease	1.59e-05	9.64e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INSR—Parkinson's disease	1.59e-05	9.64e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—ABL1—Parkinson's disease	1.58e-05	9.61e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF2—Parkinson's disease	1.58e-05	9.6e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CTGF—Parkinson's disease	1.58e-05	9.59e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—Parkinson's disease	1.56e-05	9.47e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—HGF—Parkinson's disease	1.55e-05	9.38e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—MAPK8—Parkinson's disease	1.54e-05	9.33e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—INSR—Parkinson's disease	1.53e-05	9.29e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IGF1R—Parkinson's disease	1.53e-05	9.29e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—MAPK8—Parkinson's disease	1.51e-05	9.19e-05	CbGpPWpGaD
Afatinib—ABL1—Axon guidance—IL6—Parkinson's disease	1.51e-05	9.18e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EDN1—Parkinson's disease	1.51e-05	9.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FGB—Parkinson's disease	1.5e-05	9.11e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HTR2A—Parkinson's disease	1.5e-05	9.09e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—MAPK8—Parkinson's disease	1.49e-05	9.06e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HTR1A—Parkinson's disease	1.49e-05	9.06e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—HGF—Parkinson's disease	1.49e-05	9.04e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYP2E1—Parkinson's disease	1.47e-05	8.93e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TAC1—Parkinson's disease	1.47e-05	8.92e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—MAPK8—Parkinson's disease	1.46e-05	8.84e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NQO1—Parkinson's disease	1.46e-05	8.83e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—INS—Parkinson's disease	1.45e-05	8.82e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FGB—Parkinson's disease	1.45e-05	8.78e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—DRD1—Parkinson's disease	1.44e-05	8.75e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HTR1A—Parkinson's disease	1.44e-05	8.73e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—TH—Parkinson's disease	1.43e-05	8.71e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—INS—Parkinson's disease	1.43e-05	8.68e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by NGF—IL6—Parkinson's disease	1.43e-05	8.67e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TAC1—Parkinson's disease	1.42e-05	8.6e-05	CbGpPWpGaD
Afatinib—LCK—Cytokine Signaling in Immune system—IL6—Parkinson's disease	1.4e-05	8.5e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—DRD3—Parkinson's disease	1.4e-05	8.47e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—DDC—Parkinson's disease	1.39e-05	8.44e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—NGF—Parkinson's disease	1.39e-05	8.43e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—DRD1—Parkinson's disease	1.39e-05	8.43e-05	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—HMOX1—Parkinson's disease	1.38e-05	8.39e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—CYCS—Parkinson's disease	1.38e-05	8.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling by NGF—IL6—Parkinson's disease	1.38e-05	8.36e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—DRD3—Parkinson's disease	1.35e-05	8.17e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—TNF—Parkinson's disease	1.34e-05	8.12e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HTR2A—Parkinson's disease	1.32e-05	8.03e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTA4—Parkinson's disease	1.31e-05	7.97e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ADRBK1—Parkinson's disease	1.3e-05	7.91e-05	CbGpPWpGaD
Afatinib—EGFR—Axon guidance—IL6—Parkinson's disease	1.29e-05	7.85e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—MAPK8—Parkinson's disease	1.28e-05	7.75e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HTR7—Parkinson's disease	1.26e-05	7.66e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—DRD2—Parkinson's disease	1.26e-05	7.66e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—MTHFR—Parkinson's disease	1.26e-05	7.65e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ADRBK1—Parkinson's disease	1.26e-05	7.62e-05	CbGpPWpGaD
Afatinib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—Parkinson's disease	1.23e-05	7.49e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—MAPK8—Parkinson's disease	1.23e-05	7.46e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—APOE—Parkinson's disease	1.23e-05	7.46e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—COMT—Parkinson's disease	1.22e-05	7.4e-05	CbGpPWpGaD
Afatinib—IRAK1—Innate Immune System—IL6—Parkinson's disease	1.22e-05	7.4e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HTR7—Parkinson's disease	1.22e-05	7.38e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—DRD2—Parkinson's disease	1.22e-05	7.38e-05	CbGpPWpGaD
Afatinib—LCK—Disease—MTHFR—Parkinson's disease	1.22e-05	7.38e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTP1—Parkinson's disease	1.21e-05	7.37e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL1B—Parkinson's disease	1.21e-05	7.36e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MAOA—Parkinson's disease	1.21e-05	7.35e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—HMOX1—Parkinson's disease	1.2e-05	7.27e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLA2G6—Parkinson's disease	1.18e-05	7.18e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—APOE—Parkinson's disease	1.17e-05	7.13e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MAOB—Parkinson's disease	1.17e-05	7.11e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ABCB1—Parkinson's disease	1.15e-05	6.97e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—TNF—Parkinson's disease	1.14e-05	6.94e-05	CbGpPWpGaD
Afatinib—LCK—Disease—APOE—Parkinson's disease	1.13e-05	6.87e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GSTM1—Parkinson's disease	1.12e-05	6.77e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—MAPK8—Parkinson's disease	1.11e-05	6.75e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—CASP3—Parkinson's disease	1.08e-05	6.56e-05	CbGpPWpGaD
Afatinib—ABL1—Developmental Biology—IL6—Parkinson's disease	1.08e-05	6.55e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—GPX1—Parkinson's disease	1.07e-05	6.48e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—CASP3—Parkinson's disease	1.07e-05	6.47e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF2—Parkinson's disease	1.06e-05	6.42e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—INS—Parkinson's disease	1.05e-05	6.37e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1R—Parkinson's disease	1.02e-05	6.21e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF2—Parkinson's disease	1.02e-05	6.19e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EDN1—Parkinson's disease	1.01e-05	6.14e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—INS—Parkinson's disease	1e-05	6.09e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—MAPK8—Parkinson's disease	9.94e-06	6.03e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—MTHFR—Parkinson's disease	9.86e-06	5.98e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1R—Parkinson's disease	9.86e-06	5.98e-05	CbGpPWpGaD
Afatinib—ERBB2—Immune System—IL6—Parkinson's disease	9.82e-06	5.96e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—MAPK8—Parkinson's disease	9.79e-06	5.94e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EDN1—Parkinson's disease	9.74e-06	5.91e-05	CbGpPWpGaD
Afatinib—ERBB4—Immune System—IL6—Parkinson's disease	9.67e-06	5.87e-05	CbGpPWpGaD
Afatinib—LCK—Disease—INS—Parkinson's disease	9.66e-06	5.87e-05	CbGpPWpGaD
Afatinib—ABL1—Innate Immune System—IL6—Parkinson's disease	9.54e-06	5.79e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL1B—Parkinson's disease	9.48e-06	5.76e-05	CbGpPWpGaD
Afatinib—BLK—Immune System—IL6—Parkinson's disease	9.3e-06	5.65e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NGF—Parkinson's disease	9.29e-06	5.64e-05	CbGpPWpGaD
Afatinib—EGFR—Developmental Biology—IL6—Parkinson's disease	9.23e-06	5.6e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—APOE—Parkinson's disease	9.18e-06	5.57e-05	CbGpPWpGaD
Afatinib—ERBB2—Disease—IL6—Parkinson's disease	9.06e-06	5.5e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NGF—Parkinson's disease	8.95e-06	5.43e-05	CbGpPWpGaD
Afatinib—ERBB4—Disease—IL6—Parkinson's disease	8.93e-06	5.42e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HTR2A—Parkinson's disease	8.84e-06	5.37e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2D6—Parkinson's disease	8.7e-06	5.28e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK8—Parkinson's disease	8.7e-06	5.28e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CTGF—Parkinson's disease	8.54e-06	5.18e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HTR2A—Parkinson's disease	8.52e-06	5.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APOE—Parkinson's disease	8.22e-06	4.99e-05	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—IL6—Parkinson's disease	8.15e-06	4.95e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL1B—Parkinson's disease	8.1e-06	4.92e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP2E1—Parkinson's disease	7.96e-06	4.83e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APOE—Parkinson's disease	7.92e-06	4.81e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—Parkinson's disease	7.87e-06	4.78e-05	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—Parkinson's disease	7.85e-06	4.77e-05	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—INS—Parkinson's disease	7.84e-06	4.76e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—Parkinson's disease	7.82e-06	4.75e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—Parkinson's disease	7.81e-06	4.74e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TH—Parkinson's disease	7.75e-06	4.71e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYCS—Parkinson's disease	7.45e-06	4.52e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—Parkinson's disease	7.43e-06	4.51e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—Parkinson's disease	7.19e-06	4.36e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—Parkinson's disease	7.16e-06	4.35e-05	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—Parkinson's disease	7.1e-06	4.31e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—INS—Parkinson's disease	7.02e-06	4.26e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—INS—Parkinson's disease	6.77e-06	4.11e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—COMT—Parkinson's disease	6.59e-06	4e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—Parkinson's disease	6.56e-06	3.98e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MAOA—Parkinson's disease	6.55e-06	3.97e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—Parkinson's disease	6.47e-06	3.93e-05	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—Parkinson's disease	6.35e-06	3.85e-05	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—Parkinson's disease	6.25e-06	3.8e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—Parkinson's disease	6.03e-06	3.66e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—Parkinson's disease	5.78e-06	3.51e-05	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—Parkinson's disease	5.55e-06	3.37e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—Parkinson's disease	5.33e-06	3.24e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—Parkinson's disease	5.23e-06	3.17e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—Parkinson's disease	5.19e-06	3.15e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—Parkinson's disease	5.04e-06	3.06e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—APOE—Parkinson's disease	4.96e-06	3.01e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—Parkinson's disease	4.81e-06	2.92e-05	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—Parkinson's disease	4.75e-06	2.88e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—Parkinson's disease	4.63e-06	2.81e-05	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—Parkinson's disease	4.59e-06	2.79e-05	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—Parkinson's disease	4.57e-06	2.78e-05	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—Parkinson's disease	4.38e-06	2.66e-05	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—INS—Parkinson's disease	4.24e-06	2.57e-05	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—Parkinson's disease	4.22e-06	2.56e-05	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—Parkinson's disease	3.07e-06	1.86e-05	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—Parkinson's disease	2.96e-06	1.79e-05	CbGpPWpGaD
